Intervention
mutation analysis
ClinicalTrials.gov intervention label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 27 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
27 shownHsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerNCT01259089 · 2011-04-27
COMPLETEDPositron Emission Tomography in Women With Advanced HER2-Positive Breast CancerNCT01093612 · 2011-03-16
ACTIVE_NOT_RECRUITINGBiomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib TosylateNCT01124669 · 2010-06-13
COMPLETEDCancer Genome Study Using Samples From Patients With Stage I or Stage II Non-Small Cell Lung Cancer Treated on Clinical Trial ACOSOG-Z0030NCT00899535 · 2008-10-01
COMPLETEDSorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to ChemotherapyNCT00801385 · 2008-09-01
UNKNOWNLaboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507NCT00907699 · 2008-08-01
WITHDRAWNStudy of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803NCT00897351 · 2008-07-10
COMPLETEDLapatinib Resistance in Patients With Breast CancerNCT00898573 · 2008-07-01
WITHDRAWNStudying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation CarriersNCT00897455 · 2008-04-01
UNKNOWNStudy of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung CancerNCT00989690 · 2008-02-01
UNKNOWNErlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerNCT00499655 · 2007-11-01
COMPLETEDStudy of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical TrialNCT00904514 · 2007-10-01
TERMINATEDIdentifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung CancerNCT00897143 · 2007-06-01
WITHDRAWNSWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897NCT00896623 · 2006-12-01
COMPLETEDEpidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung CancerNCT00899756 · 2006-06-01
COMPLETEDHER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598NCT00896909 · 2006-02-02
COMPLETEDStudying Patterns, Causes, and Control of Disease in Patients With Lung Cancer in the North Trent (England) RegionNCT00693836 · 2006-01-01
UNKNOWNEpidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung CancerNCT00898924 · 2005-11-01
COMPLETEDS0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung CancerNCT00450281 · 2005-10-01
COMPLETEDStudying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast DiseaseNCT00898508 · 2005-08-01
COMPLETEDBortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsNCT00389805 · 2005-03-01
COMPLETEDNeoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast CancerNCT00070278 · 2005-01-01
UNKNOWNGene Expression in Predicting Response to Paclitaxel in Patients With Breast CancerNCT00898690 · 2003-03-01
UNKNOWNStudying Urine and Blood Samples in Women With Newly Diagnosed Breast CancerNCT00766454 · 1998-11-01
COMPLETEDGene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone TherapyNCT00002924 · 1997-01-01
COMPLETEDStudy of Biomarkers in Tissue Samples From Patients With Breast CancerNCT01004796
UNKNOWNStudy of a Polymorphism in Patients With Prostate CancerNCT00900185
COMPLETEDCommon conditions
Lung Cancer12Breast Cancer9Prostate Cancer3Adenocarcinoma of the Lung1brca1 Mutation Carrier1brca2 Mutation Carrier1Cancer1Metastatic Cancer1Non-small Cell Lung Cancer1Recurrent Non-small Cell Lung Cancer1Stage IIIB Non-small Cell Lung Cancer1Stage IV Breast Cancer1Stage IV Non-small Cell Lung Cancer1Unspecified Adult Solid Tumor, Protocol Specific1
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
Leading sponsors
Alliance for Clinical Trials in Oncology
3
Case Comprehensive Cancer Center
3
City of Hope Medical Center
3
ECOG-ACRIN Cancer Research Group
3
SWOG Cancer Research Network
2
Cambridge University Hospitals NHS Foundation Trust
1
Cancer Research Centre at Weston Park Hospital
1
Gynecologic Oncology Group
1
Istituto Scientifico H. San Raffaele
1
National Cancer Institute (NCI)
1
National Institutes of Health Clinical Center (CC)
1
Northwestern University
1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
1
University of California, Davis
1
Trial status mix
COMPLETED15
UNKNOWN7
WITHDRAWN3
ACTIVE_NOT_RECRUITING1
TERMINATED1
Phase mix
PHASE24
PHASE12
PHASE32
NA1
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.